Mirati Therapeutics Inc (MRTX)


Stock Price Forecast

Jan. 22, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Mirati Therapeutics Inc chart...

About the Company

mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.

CEO

Charles Baum

Exchange

NASDAQ

Website

https://www.mirati.com/

$301M

Total Revenue

593

Employees

$4B

Market Capitalization

-4.80

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $MRTX News

Bristol Myers to Buy Mirati Therapeutics for $4.8 Billion

5mon ago, source: Hosted on MSN

(Bloomberg) -- Bristol-Myers Squibb Co. agreed to buy drugmaker Mirati Therapeutics Inc. for $4.8 billion to expand its aging portfolio of cancer drugs. Mirati shareholders will receive $58 a ...

Bristol Myers (BMY) to Acquire Mirati Therapeutics for $5.8 B

5mon ago, source: Hosted on MSN

Bristol Myers Squibb BMY announced that it will acquire commercial-stage oncology company Mirati Therapeutics, Inc.MRTX for $58.00 per share in cash, amounting to a total equity value of $4.8 ...

Mirati Therapeutics, Inc. (MRTX) stock forecast and price target

5mon ago, source: Yahoo Finance

Find the latest Mirati Therapeutics, Inc. MRTX analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

Mirati Therapeutics, Inc. Common Stock (MRTX)

4mon ago, source: Nasdaq

Nasdaq provides updated worldwide news headlines. Here you can find up-to-the-minute news and analysis of the company that you are researching for potential investment opportunities.

Bristol Myers to buy cancer specialist Mirati for up to $5.8 billion

5mon ago, source: TheStreet.com

Bristol Myers will pay up to $5.8 billion for cancer-treatment specialists Mirati, the most recent ... Turning Point Therapeutics, which focuses on oncogenesis, or the process in which healthy ...

What’s Next For Mirati Therapeutics Stock After A 20% Rise In A Month?

1y ago, source: Forbes

Opinions expressed by Forbes Contributors are their own. Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using the last ten years’ data After moving 27% or more over five days ...

Corcept Appoints Roberto Vieira as President, Oncology

1mon ago, source: Yahoo Finance

Mr. Vieira joins Corcept from Mirati Therapeutics, Inc., where he served as Senior Vice President of U.S. Commercial until earlier this month. At Mirati, Mr. Vieira built the U.S. commercial ...

Karuna Therapeutics soars after $14 billion takeover by Bristol Myers

2mon ago, source: TheStreet.com

The deal marks the second major acquisition for Bristol Myers this year, following its $5.8 billion purchase of San Diego cancer-drug specialists Mirati Therapeutics (MRTX) in October.

Ovid Therapeutics Inc OVID

13h ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

EFTR eFFECTOR Therapeutics, Inc.

4d ago, source: Seeking Alpha

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product ...

ONTX Onconova Therapeutics, Inc.

3d ago, source: Seeking Alpha

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage ...

Mirati Therapeutics, Inc. (MRTX)

1y ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...